homeostasis/metabolism
N |
• normal plasma levels of testosterone
|
Allele Symbol Allele Name Allele ID |
Nr1h4tm1Gonz targeted mutation 1, Frank Gonzalez MGI:2137330 |
||||||||||||||||||||||||
Summary |
5 genotypes
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
N |
• normal plasma levels of testosterone
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• the increase in the bile acid pool consists of increases in cholate and its derivates including taurocholic acid and taurodeoxycholic acid while other bile acids are found at normal levels
|
• total cholesterol levels in serum are about double that found in wild-type mice
|
• serum triglyceride levels are significantly higher than in control mice
|
• serum bile acids are greatly elevated in these mice
• total bile acid pool collected from liver, gallbladder and small intestine is almost 2.5-fold higher than in controls
• the increases in the bile acid pool consist of increases in cholate and its derivates including taurocholic acid and taurodeoxycholic acid
|
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• TUNEL staining indicates increased hepatocyte apoptosis as mutants age
|
• starting at 9 months of age, some mutants display preneoplasms in the liver, with small foci becoming obvious at 12 months of age
• liver damage includes many vaculoles due to lipid deposits, vaculation due to cell damage, inflammation, and focal necrosis
• significant amounts of BrdU+ cells are detected around the damaged regions of the liver suggesting initiation of a compensatory regenerative proliferation
|
• enlarged liver is not completely due to tumor formation because hepatomegaly is seen before tumors are observed
|
• both males and females develop liver tumors at 15 months of age of varying severity
• mutants fed a diet containing 2% cholestyramine, a bile acid-sequestering resin, for 3 months starting at 11 months of age when they do not have tumors, have a significantly reduced number and size of liver malignant lesions when they are older
|
• tumors are typical hepatocellular adenoma and carcinoma
|
• tumors are typical hepatocellular adenoma and carcinoma
|
• both males and females develop liver tumors at 15 months of age of varying severity
• mutants fed a diet containing 2% cholestyramine, a bile acid-sequestering resin, for 3 months starting at 11 months of age when they do not have tumors, have a significantly reduced number and size of liver malignant lesions when they are older
|
• tumors are typical hepatocellular adenoma and carcinoma
|
• tumors are typical hepatocellular adenoma and carcinoma
|
• TUNEL staining indicates increased hepatocyte apoptosis as mutants age
|
• levels of alanine aminotransferase (ALT) are much higher in aging mutants than in controls, indicating increased liver damage
|
• serum and liver bile acid levels are higher in aging mutants than in wild-type controls
|
• enlarged liver is not completely due to tumor formation because hepatomegaly is seen before tumors are observed
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
hepatocellular carcinoma | DOID:684 |
OMIM:114550 |
J:118204 , J:170790 |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
• about 30% of mutants die by day 7 when placed on a 1% cholic acid diet
|
• body weight is about 20% less than in wild-type mice, regardless of age
|
• mutants on a 1% cholic acid diet exhibit a progressive decrease in body weight that results in about 1/3 of the initial body weight by day 5 of the diet
|
• liver size, as a percentage of body weight, is higher than in wild-type mice at 12 months of age
|
• mutants on a regular diet or on a 1% cholesterol diet exhibit increased serum total cholesterol levels
|
• mutants on a regular diet or on a 1% cholesterol diet exhibit increased phospholipid levels
|
• mutants on a regular or a 1% cholesterol diet exhibit increased triglyceride levels
|
• mutants on a 1% cholic acid diet exhibit hypothermia
|
• mutants on a regular diet and 1% cholic acid diet have fecal bile acid excretion about 2-fold and 4-fold, respectively, lower than in wild-type
• mutants on a 1% cholic acid diet exhibit higher (7-fold) urinary bile acid excretion rates than wild-type on the same diet
|
• mutants on a regular diet exhibit an 8-fold increase in total serum bile acid concentration
• mutants on a 1% cholic acid diet exhibit an 23-fold increase in total serum bile acid concentration
• mutants on a regular or 1% cholic acid diet have lower bile acid pool (about by 2 fold) than wild-type
|
• 3-fold and 5.6-fold increase in serum bile acid levels in young and older mutants, respectively, compared to wild-type mice
• hepatic bile acid levels are 2x as high as in wild-type mice at 12 months of age
|
• mutants on a 1% cholesterol diet show 1.4-fold greater hepatic cholesterol levels
|
• mutants on a regular diet show 2.2-fold greater hepatic triglyceride levels
• mutants on a 1% cholesterol diet show 2.4-fold greater hepatic triglyceride levels
|
• mutants exhibit an increase in hepatocyte apoptosis as indicated by an increase in TUNEL staining; 3 month old mutants show a higher level of apoptosis than 12 month old mutants
|
• BrdU labeling indicates increased hepatocyte proliferation at 3 months of age compared to wild-type mice; at 12 months of age, proliferation has decreased but is still significantly higher than in controls
|
• mutants on a 1% cholic acid diet exhibit liver lesions indicative of severe hepatotoxicity, with numerous vacuolated and necrotic cells
|
• liver size, as a percentage of body weight, is higher than in wild-type mice at 12 months of age
|
• mutants on a 1% cholesterol diet show 1.4-fold greater hepatic cholesterol levels
|
• mutants on a regular diet show 2.2-fold greater hepatic triglyceride levels
• mutants on a 1% cholesterol diet show 2.4-fold greater hepatic triglyceride levels
|
• mutants on a regular diet or a 1% cholesterol diet exhibit more lipid containing vacuoles in the liver than wild-type
|
• 64% of mutants at 12 months of age display preneoplastic foci
• 38% total tumor incidence in 12 month old mutants; older mice were not analyzed for further tumor incidence
• both male and female mutants have liver lesions at 12 months of age; degenerative lesions consist of hypertrophic and eosinophilic hepatocytes accompanied by proliferating oval cells and lipid disposition
• 9% of mutants at 12 months of age develop mixed tumors consisting of hepatocellular carcinoma and hepatocholangiocellular carcinoma; mixed tumor involves a fibrous stroma and immune cell infiltrate, ductile formation and fibrosis
|
• 6% of mutants at 12 months of age develop hepatocellular carcinoma
|
• 36% of mutants at 12 months of age develop hepatocellular adenomas
|
• mutants exhibit an increase in hepatocyte apoptosis as indicated by an increase in TUNEL staining; 3 month old mutants show a higher level of apoptosis than 12 month old mutants
|
• BrdU labeling indicates increased hepatocyte proliferation at 3 months of age compared to wild-type mice; at 12 months of age, proliferation has decreased but is still significantly higher than in controls
|
• 64% of mutants at 12 months of age display preneoplastic foci
• 38% total tumor incidence in 12 month old mutants; older mice were not analyzed for further tumor incidence
• both male and female mutants have liver lesions at 12 months of age; degenerative lesions consist of hypertrophic and eosinophilic hepatocytes accompanied by proliferating oval cells and lipid disposition
• 9% of mutants at 12 months of age develop mixed tumors consisting of hepatocellular carcinoma and hepatocholangiocellular carcinoma; mixed tumor involves a fibrous stroma and immune cell infiltrate, ductile formation and fibrosis
|
• 6% of mutants at 12 months of age develop hepatocellular carcinoma
|
• 36% of mutants at 12 months of age develop hepatocellular adenomas
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
hepatocellular carcinoma | DOID:684 |
OMIM:114550 |
J:121075 , J:170790 |
|
|
♀ | phenotype observed in females |
♂ | phenotype observed in males |
N | normal phenotype |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/12/2024 MGI 6.24 |
|
|